Business
Directorate Change
Directorate Change.
About this update from Theracryf Plc
[{"type":"text","content":"\n \n \n RNS Number : 3902L\n Evgen Pharma PLC\n 30 April 2020\n \n \n \n \n Evgen Pharma plc\n \n \n \n \n \n (\"Evgen Pharma\" or the \"Company\")\n \n \n \n \n \n Directorate Change\n \n \n \n \n \n Evgen Pharma plc\n (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the resignation with immediate effect of Dr. Stephen Franklin as Chief Executive Officer of the Company. Having led Evgen for over 12 years Steve has, with the support of the Board, decided to pursue other opportunities. \n \n \n \n \n Barry Clare will become Executive Chairman on a temporary basis until a new CEO is appointed with the appropriate experience to take Evgen through the next exciting stages of its development. Barry, together with our strong group of Non-Executive Directors; Susan Clement-Davies, Sue Foden and Alan Barge, will support the executive team on business development and pre-clinical and clinical projects. The Company remains committed to developing sulforaphane-based medicines for the treatment of breast cancer and multiple other diseases and continues to collaborate with its various hospital and university partners.\n \n \n \n \n The search for a replacement to fill the role is underway and the Company will update the market in due course. \n \n \n \n \n \n \n Barry Clare, Non-Executive Chairman, said\n \n : \"On behalf of the Board, I would like to extend our sincere gratitude to Steve for all his efforts and his guidance since Evgen's inception. His contribution to the Company over the years has been invaluable and we would like to offer our huge thanks for all his support and hard work. We wish him all the best in his future endeavours.\"\n \n \n \n \n \n The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n \n \n \n Enquiries:\n \n \n \n \n Evgen\n Pharma\n \n plc\n \n \n www.evgen.com\n \n \n \n \n \n \n via Walbrook\n \n \n \n \n \n \n \n Barry Clare, Chairman \n \n \n \n \n \n \n \n \n \n Richard Moulson, CFO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n finnCap\n \n \n www.finncap.com\n \n \n \n \n \n \n +44 (0)20 7220 0500\n \n \n \n \n \n \n Geoff Nash / T...